Pediatric rhabdomyosarcoma

Stephanie A Terezakis, Matthew Ladra

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pediatric rhabdomyosarcoma (RMS) composes just under one half of all pediatric soft tissue sarcomas in the United States (US) (Li et al. 2008). It is a highly malignant neoplasm, originating from mesenchymal cells destined for striated muscle differentiation. It can arise anywhere in the body, including the head and neck (35%), genitourinary tract (24%), extremities (19%), and elsewhere (22%) (Pappo 1995). Pediatric RMS treatment represents a diverse and challenging paradigm, due to the differing prognoses based on site of origin and histology. Chemotherapy comprises the backbone of curative treatment, as RMS tends to disseminate early in its course, with surgery and/or radiotherapy used for local control of the primary site. Since the creation of the Intergroup Rhabdomyosarcoma Study Group (IRSG) in the early 1970s, rates of cure have steadily increased from 15 to 20% in the earliest studies to currently better than 80% for all non-metastatic patients (Crist et al. 1990, 2001; Maurer et al. 1993; Arndt et al. 2009; Raney et al. 2011).

Original languageEnglish (US)
Title of host publicationPediatric Oncology
PublisherSpringer Verlag
Pages21-43
Number of pages23
Edition9783319435442
DOIs
StatePublished - Jan 1 2018

Publication series

NamePediatric Oncology
Number9783319435442
ISSN (Print)1613-5318
ISSN (Electronic)2191-0812

Fingerprint

Rhabdomyosarcoma
Pediatrics
Striated Muscle
Sarcoma
Histology
Neck
Radiotherapy
Extremities
Head
Drug Therapy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology

Cite this

Terezakis, S. A., & Ladra, M. (2018). Pediatric rhabdomyosarcoma. In Pediatric Oncology (9783319435442 ed., pp. 21-43). (Pediatric Oncology; No. 9783319435442). Springer Verlag. https://doi.org/10.1007/978-3-319-43545-9_3

Pediatric rhabdomyosarcoma. / Terezakis, Stephanie A; Ladra, Matthew.

Pediatric Oncology. 9783319435442. ed. Springer Verlag, 2018. p. 21-43 (Pediatric Oncology; No. 9783319435442).

Research output: Chapter in Book/Report/Conference proceedingChapter

Terezakis, SA & Ladra, M 2018, Pediatric rhabdomyosarcoma. in Pediatric Oncology. 9783319435442 edn, Pediatric Oncology, no. 9783319435442, Springer Verlag, pp. 21-43. https://doi.org/10.1007/978-3-319-43545-9_3
Terezakis SA, Ladra M. Pediatric rhabdomyosarcoma. In Pediatric Oncology. 9783319435442 ed. Springer Verlag. 2018. p. 21-43. (Pediatric Oncology; 9783319435442). https://doi.org/10.1007/978-3-319-43545-9_3
Terezakis, Stephanie A ; Ladra, Matthew. / Pediatric rhabdomyosarcoma. Pediatric Oncology. 9783319435442. ed. Springer Verlag, 2018. pp. 21-43 (Pediatric Oncology; 9783319435442).
@inbook{531f635c35c944ddad53261b900b3420,
title = "Pediatric rhabdomyosarcoma",
abstract = "Pediatric rhabdomyosarcoma (RMS) composes just under one half of all pediatric soft tissue sarcomas in the United States (US) (Li et al. 2008). It is a highly malignant neoplasm, originating from mesenchymal cells destined for striated muscle differentiation. It can arise anywhere in the body, including the head and neck (35{\%}), genitourinary tract (24{\%}), extremities (19{\%}), and elsewhere (22{\%}) (Pappo 1995). Pediatric RMS treatment represents a diverse and challenging paradigm, due to the differing prognoses based on site of origin and histology. Chemotherapy comprises the backbone of curative treatment, as RMS tends to disseminate early in its course, with surgery and/or radiotherapy used for local control of the primary site. Since the creation of the Intergroup Rhabdomyosarcoma Study Group (IRSG) in the early 1970s, rates of cure have steadily increased from 15 to 20{\%} in the earliest studies to currently better than 80{\%} for all non-metastatic patients (Crist et al. 1990, 2001; Maurer et al. 1993; Arndt et al. 2009; Raney et al. 2011).",
author = "Terezakis, {Stephanie A} and Matthew Ladra",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-43545-9_3",
language = "English (US)",
series = "Pediatric Oncology",
publisher = "Springer Verlag",
number = "9783319435442",
pages = "21--43",
booktitle = "Pediatric Oncology",
edition = "9783319435442",

}

TY - CHAP

T1 - Pediatric rhabdomyosarcoma

AU - Terezakis, Stephanie A

AU - Ladra, Matthew

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Pediatric rhabdomyosarcoma (RMS) composes just under one half of all pediatric soft tissue sarcomas in the United States (US) (Li et al. 2008). It is a highly malignant neoplasm, originating from mesenchymal cells destined for striated muscle differentiation. It can arise anywhere in the body, including the head and neck (35%), genitourinary tract (24%), extremities (19%), and elsewhere (22%) (Pappo 1995). Pediatric RMS treatment represents a diverse and challenging paradigm, due to the differing prognoses based on site of origin and histology. Chemotherapy comprises the backbone of curative treatment, as RMS tends to disseminate early in its course, with surgery and/or radiotherapy used for local control of the primary site. Since the creation of the Intergroup Rhabdomyosarcoma Study Group (IRSG) in the early 1970s, rates of cure have steadily increased from 15 to 20% in the earliest studies to currently better than 80% for all non-metastatic patients (Crist et al. 1990, 2001; Maurer et al. 1993; Arndt et al. 2009; Raney et al. 2011).

AB - Pediatric rhabdomyosarcoma (RMS) composes just under one half of all pediatric soft tissue sarcomas in the United States (US) (Li et al. 2008). It is a highly malignant neoplasm, originating from mesenchymal cells destined for striated muscle differentiation. It can arise anywhere in the body, including the head and neck (35%), genitourinary tract (24%), extremities (19%), and elsewhere (22%) (Pappo 1995). Pediatric RMS treatment represents a diverse and challenging paradigm, due to the differing prognoses based on site of origin and histology. Chemotherapy comprises the backbone of curative treatment, as RMS tends to disseminate early in its course, with surgery and/or radiotherapy used for local control of the primary site. Since the creation of the Intergroup Rhabdomyosarcoma Study Group (IRSG) in the early 1970s, rates of cure have steadily increased from 15 to 20% in the earliest studies to currently better than 80% for all non-metastatic patients (Crist et al. 1990, 2001; Maurer et al. 1993; Arndt et al. 2009; Raney et al. 2011).

UR - http://www.scopus.com/inward/record.url?scp=85043249156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043249156&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-43545-9_3

DO - 10.1007/978-3-319-43545-9_3

M3 - Chapter

AN - SCOPUS:85043249156

T3 - Pediatric Oncology

SP - 21

EP - 43

BT - Pediatric Oncology

PB - Springer Verlag

ER -